Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2008-12-02
2011-11-29
Li, Bao (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C424S093100
Reexamination Certificate
active
08067531
ABSTRACT:
Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
REFERENCES:
patent: 4534966 (1985-08-01), Ohnishi et al.
patent: 5002766 (1991-03-01), Ransberger et al.
patent: 5436143 (1995-07-01), Hyman
patent: 5872210 (1999-02-01), Medabalimi
patent: 6165794 (2000-12-01), Craik et al.
patent: 6461615 (2002-10-01), Srivastava
patent: 6534310 (2003-03-01), Craik et al.
patent: 6719974 (2004-04-01), Rothman et al.
patent: 6979566 (2005-12-01), Friedman et al.
patent: 2002/0192797 (2002-12-01), Dash et al.
patent: 2004/0005557 (2004-01-01), Padigaru et al.
patent: 2004/0038330 (2004-02-01), Nagaoka
patent: 678202 (1995-12-01), None
patent: WO/2007/041285 (2007-12-01), None
Rebecca L. O'Brien et al., “Heat Shock Protein Hsp60-reactive cells: A Large, Diversified T-lymphocyte Subset with Highly Focused Specificity” 5 pgs, Jan. 2, 1992.
Srivastava, P. (2002). Interactions of heat shock proteins with peptides and antigen presenting cells Annu. Rev. immunol. 20: 395-425.
Suzue K. and Young RA. Heat shock proteins as immunological carriers and vaccines. PubMed PMID 8856990. In: Stress-inducible Cellular Response, ed. U. Fiege, Birkhauser (1996) 77: 451-465.
Murray P. and Young RA. Stress and Immunological recognition in host-pathogen interaction. ,J Bacteriol (1992) vol. 174, No. 13, p. 4193-4196.
Suto, R. and Srivastava, P.K 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science Sep. 15, 1995; 269; 1585-8.
Vabulas, R. M., Wagner, H. and Schild, H. (2002). Heat shock proteins as ligands of toll-like receptors. Curr. Topics Microbiol.lmmunol. 270; 169.
Sigal LJ., Crotty S., Andino R. and Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cell requires presentation of exogenous antigen. Nature (1999) 398:77 80.
Derky CS. Task force on recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg (1995) 121: 1386-1391.
Panjwani, N. N., Popova, L, Febbraio, M and Srivastava, P. K. (2001) CD91 is common receptor for heat shock proteins gp96, HSP 90, HSP70 and calreticulin. Immunity 14:303.
Srivastava, P. K., Deleo, A. B. and Old, L. J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Nat. Acad. Sci. USA. vol. 83:3407-11 May 1986.
Pockley, G. A. Heat Shock proteins in health and disease: therapeutic targets or therapeutic agents? Exp. Rev. Mol. Med. Sep. 21, 2001 http://www.ermm.cbcu.cam.ac.uk/01003556h.htm.
Parmiani, G. et al., Heat Shock Proteins and Their Use as Anticancer Vaccines. Clinical Cancer Research. vol. 10, 8142-8146. Dec. 15, 2004.
Gritti, I., Banfi, G., and Roi, G.S., Pepsinogens: Physiology, Pharmacology Pathophysiology and Exercise. Pharmacological Research. vol. 41. Nov. 3, 2000.
U.S. Appl. No. 10/336,512, filed Jan. 29, 2004, Zhabilov.
Lin, X-L. et al. Synthesis, Purification and Active Site Mutagenesis of Recombinant Porcine Pepsinogen, J. Biolog. Chem. Mar. 15, 1989, pp. 4482-4489, vol. 264, No. 8.
Filippova, I. et al. Fluorogenic Peptide Substrates for Assay of Asparty Proteinases, Analytical Biochemistry, Mar. 1996, pp. 113-118, vol. 234, see entire document.
Pockley, A. Heat Shock Proteins in Health and Disease: Theraputic Targets or Theraputic Agents?. Expert Reviews in Molucular Medicine. Sep. 21, 2001.
Sreedhar, A. et al. Heat Shock Proteins in the Regulation of Apoptosis: New Strategies in Tumor . . . Pharmacology & Therapeutics. Mar. 2004, pp. 227-257, vol. 101, No. 3.
Kamatari et al. Structural Dissection of Alkaline-denatured Pepsin. Science. 2003, pp. 717-724, vol. 12.
Campos et al. The Active Site of Pepsin is Formed in the Intermediate Conformation Dominant at Mildly Acidic pH. FEBS Letters. 2003, pp. 89-95, vol. 538.
Harlow, E. et al. Antibodies: A Labratory Manuel, 1988, pp. 626-628, Cold Springs Harbor, NY.
Boyd, M.R. AIDS Etiology: Diagnosis, Treatment, and Prevention. Lippincott. 1988, pp. 305-319.
Sigal, L. et al. Cytotoxic T-cell Immunity to Virus-Infected Non-haematic Cells . . . , Nature, 1999, pp. 77-80, Issue 398.
Gulakowski, R., Laboratory of Drug Discovery Research and Development, Journal of Virological Methods, Jun. 1991, pp. 87-100, vol. 33, No. 1-2.
Tang, J. et al., Amino-Acid Sequence of Porcine Pepsin, Proceedings of the National Academy of Sciences, Dec. 1973, pp. 3437-3439, vol. 70, No. 12.
Weissenhorn, W. et al., Atomic Structure of the Ectodomain from HIV-1 gp41, Nature, May 22, 1997, pp. 426-430, No. 387.
Kirk, R., et al., A Nonpromoting Phorbol from Samoan Medicinal PlantHomalanthus Nutans. . . , Journal of Medicinal Chemistry, 1992, pp. 1978-1986, vol. 35, No. 11.
Moore, J. et al., HIV Envelope's Letters Boxed into Shape, Nature, Jun. 18, 1998, pp. 630-631, No. 393.
Weislow, O. et al., New Soluable-formazan Assay for HIV-1 Cytopathic Effects . . . , Joumal of the National Cancer Institute, Jun. 21, 1989, p. 963, vol. 81, No. 12.
Laemmli, U., Cleavage of Structural Proteins During the Assembly of the Head Bacteriophage T4, Nature, Aug. 15, 1970, pp. 680-685.
Pockley, A., Heat Shock Proteins in Health and Disease . . . (Figure 4), Expert Reviews in Molecular Medicine, Sep. 21, 2001.
Radsak, M., The Heat Shock Protein Gp96 Binds to Human Neutrophils and Monocytes and Stimmulates Effector Functions, Blood, Apr. 1, 2003, pp. 2810-2815, vol. 101, No. 7.
Weissenhorn, W., Structural Basis for Membrane Fusion by Envelope Viruses, Molecular Membrane Biology, Jan. 1, 1999, pp. 3-9, vol. 1, No. 1.
Supplementary European Search Report, EP 05 85 0002, Oct. 1, 2010.
Sogawa K et al: “Molecular Cloning of Complementary DNA to Swine Pesinogen Messenger RNA”, Journal of Biological Chemistry, vol. 256, No. 23, 1981, pp. 12561-12565.
Tanaka T et al: “N-terminal portion acts as an initiator of the inactivation of pepsin at neutral pH.” Protein Engineering Sep. 2001, vol. 14, No. 9, pp. 669-674.
Jiang S et al: “Peptide and Non-Peptide HIV Fusion Inhibitors,” Current Pharamecutical Design, Bentham Science Publishers, vol. 8, No. 8, Jan. 2002, pp. 563-580.
Yu F.I. et al: “Fluorogenic Peptide Substrates for Assay for Aspartyl Proteinases,” Analytical Biochemistry. vol. 234, Mar. 1996, pp. 113-188.
Cislo & Thomas LLP
Li Bao
The Zhabilov Trust
LandOfFree
Inactivated pepsin fragments for modulating immune system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inactivated pepsin fragments for modulating immune system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inactivated pepsin fragments for modulating immune system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254389